Sort
10,766 grants matching “checkpoint inhibitor”
Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response
$593,078Brendan D Curti · Providence Portland Medical Center · R01 · FY2021 · CA
Dysregulated Complement Pathway in Macrophage Reprogramming and Progression of HCC in MASH
$593,042Renumathy Dhanasekaran · Stanford University · R37 · FY2025 · CA
The role of IL-6/STAT3 signaling in CIC-DUX4 fusion sarcoma metastasis and immunosuppression
$593,028Hua E Yu · Beckman Research Institute/City Of Hope · R01 · FY2025 · CA
Immune Exclusion in Cancer Immunotherapy
$592,843Riyue Bao · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · DE
The Duke Preclinical Research Resources for Quantitative Imaging Biomarkers
$592,709Cristian T Badea · Duke University · U24 · FY2017 · CA
Lung Cancer Early Detection and Immunotherapy Response Prediction and Monitoring with an Exo-PROS Liquid Biopsy Assay
$592,674Yun Wu · State University Of New York At Buffalo · R01 · FY2022 · CA
Generation of tumor specific immunity in canine osteosarcoma through dendritic cell hyperactivation
$592,532Cheryl A London · Tufts University Boston · U01 · FY2025 · CA
HLA B44 motif neoepitopes in NSCLC: Evaluating their effects on the TME and adding them to established markers in a model to predict durable benefit from PD- 1 inhibition with and without chemotherapy
$592,352Edward B Garon · University Of California Los Angeles · R01 · FY2024 · CA
RP-3: Elucidating Mechanisms of Sensitivity and Resistance to Checkpoint Blockade Therapy for Rational Multi-Drug Immunotherapy in Urothelial Cancers
$592,269Jonathan Eric Rosenberg · Sloan-Kettering Inst Can Research · P50 · FY2021 · CA
Cell type-directed Tim-3 targeting in melanoma
$592,227Steven Russell Barthel · Brigham And Women'S Hospital · R01 · FY2022 · CA
Mechanism of spontaneous and DSB-induced repair
$592,173Rodney J. Rothstein · Columbia University Health Sciences · R37 · FY2013 · GM
Identifying and targeting neoantigens in aggressive salivary carcinomas
$592,082Luc Gordon Trang Morris · Sloan-Kettering Inst Can Research · R01 · FY2019 · DE
Streptococcus species as potential therapeutics for oropharyngeal squamous cell carcinoma
$592,080Stephanie Dorta-Estremera · University Of Puerto Rico Med Sciences · R16 · FY2025 · DE
Signaling Mechanisms in Genome Maintenance
$592,077Marcus Smolka · Cornell University · R35 · FY2022 · GM
Signaling Mechanisms in Genome Maintenance
$592,066Marcus Smolka · Cornell University · R35 · FY2023 · GM
Signaling Mechanisms in Genome Maintenance
$592,065Marcus Smolka · Cornell University · R35 · FY2025 · GM
Signaling Mechanisms in Genome Maintenance
$592,065Marcus Smolka · Cornell University · R35 · FY2024 · GM
Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy
$591,868Farrokh Dehdashti · Washington University · R01 · FY2022 · CA
Serial immunotherapy combination to modulate the tumor environment in patients with metastatic gastroesophageal cancer
$591,765Harry H Yoon · Mayo Clinic Rochester · R01 · FY2024 · CA
Translating Autoantibodies Into Chimeric Antigen Receptor-T cell Therapy for Small Cell Lung Cancer
$591,527Kristin J Lastwika · Fred Hutchinson Cancer Center · U01 · FY2023 · CA
Eco-Evolutionary dynamics of NSCLC to immunotherapy: Response and Resistance
$591,459Alexander Robertson Allan Anderson · H. Lee Moffitt Cancer Ctr & Res Inst · U01 · FY2022 · CA
A Phase 1 Trial of MLN0128 (sapanisertib) and CB-839 HCl (telaglenastat) in Advanced NSCLC Patients
$591,444Paul K Paik · Sloan-Kettering Inst Can Research · R01 · FY2022 · CA
Homologous recombination deficiency and beyond in pancreatic cancer: evaluating the regulators of response to pembrolizumab and olaparib (POLAR) from the immune and genomic perspectives
$591,430Eileen Mary O'Reilly · Sloan-Kettering Inst Can Research · P50 · FY2025 · CA
Modulation of the tumor microenvironment with probiotic therapies
$591,316Tal Danino · Columbia Univ New York Morningside · R01 · FY2020 · CA
Targeted immuno-nanoparticles for directing antitumor immune response against breast cancer metastasis
$591,126Efstathios Karathanasis · Case Western Reserve University · R01 · FY2021 · CA